EVONILE PHARMA LIMITED (EVONILE) financials

EVONILE PHARMA LIMITED (EVONILE) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods.[1]It imports various medicines to India from different sources across the globe.[2]

Market Cap: ₹4,241Cr.
Current Price: ₹1,718
Stock P/E: 43.4
ROE: 11.6%
ROCE: 16.3%
Book Value: ₹331
Dividend Yield: 0.00%
52W High / Low: ₹2,589/750

In Jun 2026, EVONILE PHARMA LIMITED (EVONILE) reported sales ₹104 Cr and net profit ₹32 Cr.

Annual TTM: sales ₹371 Cr, net profit ₹98 Cr.

Shareholding: Promoters 70.68% (Sep 2026), FIIs 1.21% (Sep 2026), DIIs 1.50% (Sep 2026), Public 26.61% (Sep 2026), No. of Shareholders 38,127% (Sep 2026).

EVONILE quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	87	93	84	88	90	86	91	104
Expenses	69	67	60	60	66	64	70	69
Operating Profit	18	26	24	27	24	22	21	35
OPM %	21%	28%	29%	31%	26%	26%	23%	34%
Other Income	10	11	11	11	9	9	10	9
Interest	0	0	0	0	0	1	0	0
Depreciation	1	1	1	1	1	0	0	0
Profit before tax	28	35	34	37	33	30	30	43
Tax %	26%	28%	14%	26%	26%	46%	16%	25%
Net Profit	20	25	29	28	24	16	25	32
EPS in Rs	8.27	10.31	11.87	11.19	9.81	6.52	10.23	13.05
Raw PDF	—	—	—	—	—	—	—	—

EVONILE profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	438	381	400	379	335	356	354	371
Expenses	426	355	373	314	270	265	260	269
Operating Profit	12	27	27	65	65	91	94	102
OPM %	2.8%	7%	7%	17%	19%	26%	27%	27%
Other Income	36	33	-17	58	62	42	39	37
Interest	6	8	5	2	1	1	1	1
Depreciation	13	12	10	6	3	2	2	2
Profit before tax	29	40	-4	115	123	130	130	136
Tax %	65%	48%	-3%	10%	31%	23%	28%	—
Net Profit	10	21	-4	103	85	101	93	98
EPS in Rs	4.08	8.46	-1.51	41.86	34.50	40.87	37.74	39.61
Dividend Payout %	245%	118%	-663%	113%	72%	61%	66%	—

EVONILE balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	12	12	12	12	12	12	12	12
Reserves	747	708	699	679	763	732	773	805
Borrowings	0	68	62	24	22	7	5	3
Other Liabilities	223	289	229	242	186	173	158	157
Total Liabilities	982	1,078	1,002	958	983	925	948	978
Fixed Assets	15	76	64	24	19	7	5	3
CWIP	0	0	0	0	0	0	0	0
Investments	0	0	0	0	0	0	0	0
Other Assets	967	1,001	938	934	964	918	943	975
Total Assets	982	1,078	1,002	958	983	925	948	978

EVONILE cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-194	-23	-69	39	45	113	75	47
Cash from Investing Activity	274	56	95	87	-153	33	-3	18
Cash from Financing Activity	-30	-41	-37	-36	-30	-121	-64	-64
Net Cash Flow	50	-9	-11	90	-139	26	7	0
Free Cash Flow	-208	-24	-69	38	45	113	75	46
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	-1,210%	124%	-127%	210%	65%	115%	99%	87%

EVONILE shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	70.68%	70.68%	70.68%	70.68%	70.68%	70.68%	70.68%	70.68%
FIIs	0.19%	0.19%	0.19%	0.19%	0.19%	0.17%	0.16%	1.21%
DIIs	0.53%	0.53%	0.53%	0.53%	0.63%	0.53%	1.35%	1.50%
Public	28.60%	28.61%	28.60%	28.61%	28.50%	28.60%	27.81%	26.61%
No. of Shareholders	38,926	39,133	39,040	39,353	39,468	38,116	36,502	38,127

EVONILE key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	34	31	37	41	35	45	41	38
Inventory Days	111	117	119	117	99	82	74	98
Days Payable	168	145	137	148	108	112	93	101
Cash Conversion Cycle	-23	3	19	10	26	15	22	36
Working Capital Days	7	-1	62	-23	-37	-59	-45	-46
ROCE %	12%	5%	6%	6%	15%	16%	17%	16%

EVONILEUpdated 3 Nov 2026, 7:51

Evonile Pharma Limited

EVONILEUpdated 3 Nov 2026, 7:51

Market Cap

₹4,241Cr.

Current Price

₹1,718

High / Low

₹2,589/750

Stock P/E

43.4

ROE11.6%

ROCE16.3%

Book Value₹331

Face Value₹5.00

Dividend Yield0.00%

About

Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods.[1]It imports various medicines to India from different sources across the globe.[2]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	91	0	73	12	2	28	27	20	8.21
Sep 2023	79	1	62	17	1	32	27	24	9.59
Dec 2023	85	0	65	22	0	41	36	27	10.76
Mar 2024	81	0	70	10	0	21	31	15	5.95
Jun 2024	92	0	68	10	1	34	24	26	10.42
Sep 2024	87	0	69	10	1	28	26	20	8.27
Dec 2024	93	0	67	11	1	35	28	25	10.31
Mar 2025	84	0	60	11	1	34	14	29	11.87
Jun 2025	88	0	60	11	1	37	26	28	11.19
Sep 2025	90	0	66	9	1	33	26	24	9.81
Dec 2025	86	1	64	9	0	30	46	16	6.52
Mar 2026	91	0	70	10	0	30	16	25	10.23
Jun 2026	104	0	69	9	0	43	25	32	13.05

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	870	0	874	101	4	93	15	79	24.75
Mar 2016	690	0	656	207	3	237	16	198	62.04
Mar 2017	656	1	631	71	4	92	38	57	20.33
Mar 2018	564	6	570	172	3	158	50	78	31.74
Mar 2019	491	2	478	78	3	86	40	52	20.97
Mar 2020	438	6	426	36	13	29	65	10	4.08
Mar 2021	381	8	355	33	12	40	48	21	8.46
Mar 2022	400	5	373	-17	10	-4	-3	-4	-1.51
Mar 2023	379	2	314	58	6	115	10	103	41.86
Mar 2024	335	1	270	62	3	123	31	85	34.5
Mar 2025	356	1	265	42	2	130	23	101	40.87
Mar 2026	354	1	260	39	2	130	28	93	37.74
TTM	371	1	269	37	2	136	—	98	39.61

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	70.68%
FIIs	1.21%
DIIs	1.5%
Public	26.61%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	70.68%	0.19%	0.52%	28.6%
Mar 2024	70.68%	0.19%	0.52%	28.61%
Jun 2024	70.68%	0.19%	0.52%	28.6%
Sep 2024	70.68%	0.19%	0.52%	28.61%
Dec 2024	70.68%	0.19%	0.53%	28.6%
Mar 2025	70.68%	0.19%	0.53%	28.61%
Jun 2025	70.68%	0.19%	0.53%	28.6%
Sep 2025	70.68%	0.19%	0.53%	28.61%
Dec 2025	70.68%	0.19%	0.63%	28.5%
Mar 2026	70.68%	0.17%	0.53%	28.6%
Jun 2026	70.68%	0.16%	1.35%	27.81%
Sep 2026	70.68%	1.21%	1.5%	26.61%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	Other Assets	Total Assets
Mar 2015	16	986	0	244	1246	8	1238	1246
Mar 2016	16	1178	0	239	1433	6	1426	1433
Mar 2017	14	906	0	230	1150	6	1144	1150
Mar 2018	12	721	0	377	1111	5	1106	1111
Mar 2019	12	747	0	223	982	15	967	982
Mar 2020	12	708	68	289	1078	76	1001	1078
Mar 2021	12	699	62	229	1002	64	938	1002
Mar 2022	12	679	24	242	958	24	934	958
Mar 2023	12	763	22	186	983	19	964	983
Mar 2024	12	732	7	173	925	7	918	925
Mar 2025	12	773	5	158	948	5	943	948
Mar 2026	12	805	3	157	978	3	975	978

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	-60	719	-38	622
Mar 2016	57	-630	-39	-612
Mar 2017	-41	424	-332	51
Mar 2018	161	69	-268	-38
Mar 2019	-194	274	-30	50
Mar 2020	-23	56	-41	-9
Mar 2021	-69	95	-37	-11
Mar 2022	39	87	-36	90
Mar 2023	45	-153	-30	-139
Mar 2024	113	33	-121	26
Mar 2025	75	-3	-64	7
Mar 2026	47	18	-64	0

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	35	27	23	28	34	31	37	41	35	45	41	38
Inventory Days	103	92	104	84	111	117	119	117	99	82	74	98
Days Payable	98	89	87	158	168	145	137	148	108	112	93	101
Cash Conversion Cycle	40	30	40	-45	-23	3	19	10	26	15	22	36
Working Capital Days	6	-35	-14	-99	7	-1	62	-23	-37	-59	-45	-46
ROCE %	9%	22%	9%	17%	12%	5%	6%	6%	15%	16%	17%	16%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of EVONILE PHARMA LIMITED (EVONILE)?

The reported market capitalisation for EVONILE PHARMA LIMITED (EVONILE) is ₹4,241Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of EVONILE?

The current price shown for EVONILE PHARMA LIMITED (EVONILE) on Fincrux is ₹1,718 with a 52-week high/low of ₹2,589/750.

What is the P/E ratio of EVONILE PHARMA LIMITED (EVONILE)?

The stock P/E for EVONILE PHARMA LIMITED (EVONILE) is 43.4 on Fincrux, with ROE at 11.6% and ROCE at 16.3%.

What were EVONILE latest quarterly results?

For Jun 2026, EVONILE PHARMA LIMITED (EVONILE) reported sales ₹104 Cr and net profit ₹32 Cr (figures in ₹ crore unless noted).

What are EVONILE annual sales and net profit?

For TTM, EVONILE PHARMA LIMITED (EVONILE) shows sales of ₹371 Cr and net profit of ₹98 Cr on the Fincrux profit & loss statement.

Who owns EVONILE PHARMA LIMITED (EVONILE)?

Latest shareholding for EVONILE PHARMA LIMITED (EVONILE) on Fincrux: Promoters 70.68% (Sep 2026), FIIs 1.21% (Sep 2026), DIIs 1.50% (Sep 2026), Public 26.61% (Sep 2026), No. of Shareholders 38,127% (Sep 2026).

Where can I find EVONILE PHARMA LIMITED (EVONILE) financials?

EVONILE PHARMA LIMITED (EVONILE) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show EVONILE balance sheet and cash flow?

Yes. The EVONILE PHARMA LIMITED (EVONILE) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 3 November 2026 at 7:51